<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center; text-indent: 0in"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Washington, D.C. 20549
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4.5pt 0 0; text-align: center; text-indent: 0in"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 4.5pt 0 0; text-align: center; text-indent: 0in"><B>CURRENT REPORT
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center; text-indent: 0in"><B>Pursuant to Section&nbsp;13
or 15(d) of the </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Securities Exchange Act
of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center; text-indent: 0in"><B>Date of Report (Date
of earliest event reported): February 14, 2014 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 4.5pt 0 0; text-align: center; text-indent: 0in"><B>NEPHROGENEX, INC.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>(Exact name of registrant
as specified in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-indent: 0in; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-indent: 0in; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-36303</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-indent: 0in; text-align: center"><FONT STYLE="font-size: 10pt"><B>20-1295171</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 8pt"><B>(state
        or other jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 8pt"><B>of
        incorporation)</B></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 8pt"><B>(Commission</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 8pt"><B>File
        Number)</B></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 8pt"><B>(I.R.S.
        Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 8pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>79 T.W. Alexander Drive</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>4401 Research Common Building</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Suite 290</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>P.O. Box 14188</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt; text-align: center; text-indent: 0in"><B>Research Triangle
        Park, NC </B></P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in; text-align: center"><FONT STYLE="font-size: 10pt"><B>27709</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-indent: 0in; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Address
    of principal executive offices)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-indent: 0in; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Zip
    Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center; text-indent: 0in"><B>Registrant&#8217;s
telephone number, including area code: (609)&nbsp;986-1780 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25in 0 0; text-align: center; text-indent: 0in"><B>(Former name or
former address, if changed since last report) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.5pt 0 0; text-indent: 0in">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt; text-indent: 0in"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt; text-indent: 0in"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt; text-indent: 0in"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt; text-indent: 0in"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.5pt 0 0; text-indent: 0in"><B>Item 5.02&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B>(d)&#9;</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February 14, 2014, James Mitchum became a member of board of directors of NephroGenex, Inc. (the &#8220;Company&#8221;). As described
in the Registration Statement on Form S-1 (File No.&nbsp;333-193023) (the &#8220;Registration Statement&#8221;), the Company&#8217;s
board of directors previously approved the appointment of Mr. Mitchum to the Company&#8217;s board of directors, effective upon
the completion of the Company&#8217;s initial public offering. Mr. Mitchum will be a Class II director with his term expiring
at the annual meeting of stockholders to be held in 2015. Mr. Mitchum has agreed to serve as a member of the audit committee and
the compensation committee of the Company&#8217;s board of directors. There are no arrangements or understandings between the
Company and any other person pursuant to which Mr. Mitchum was selected as a director, nor are there any transactions between
Mr. Mitchum and the Company in which he has a direct or indirect material interest that the Company is required to report except
as set forth below.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">From 2009 to July 2012, Mr. Mitchum served as
President of the Americas for EUSA Pharma (USA), Inc., where he oversaw the streamlining of that business as well as the development,
FDA approval and successful launch of a pediatric oncology drug in 2011. From 2005 to 2008, Mr. Mitchum served as President and
Chief Executive Officer of Enturia, Inc., a privately owned drug-device company, based in Kansas City, Missouri. From 2004 to 2005,
Mr. Mitchum served as the President and Chief Executive Officer of Sanofi-Aventis Group Japan. Mr. Mitchum has also served as a
director on numerous private company and organization boards. Mr. Mitchum earned an MBA in Business from the University of Tennessee
in Knoxville, Tennessee and a Bachelor of Science degree in Business and Math from Milligan College in Johnson City, Tennessee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
the date of this Current Report on Form 8-K, </FONT>in connection with his appointment as a director, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Company&#8217;s board of directors, subject to an increase in the amount of available options at the next annual meeting, granted
</FONT>Mr. Mitchum options to purchase 3,076 shares of the Company&#8217;s common stock, par value $0.001, at fair market value
under the Company&#8217;s 2005 Stock Option Plan, as amended and restated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.5pt 0 0; text-indent: 0in"><B>Item 5.03&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments to Articles
of Incorporation or Bylaws; Change in Fiscal Year.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0in"><B>(a)&#9;</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendment and Restatement
of Certificate of Incorporation </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0.5in">On February&nbsp;14, 2014, the Company
filed a restated certificate of incorporation (the &#8220;Restated Certificate&#8221;) with the Secretary of State of the State
of Delaware in connection with the closing of the Company&#8217;s initial public offering of shares of its common stock. As described
in the Registration Statement, the Company&#8217;s board of directors and stockholders previously approved the Restated Certificate
to be effective upon the closing of the initial public offering. The Restated Certificate amends and restates in its entirety the
Company&#8217;s restated certificate of incorporation, as amended to, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>authorize 100,000,000 shares of common stock; holders of common stock are entitled to one vote for each share held of record
on all matters submitted to a vote of the stockholders, and do not have cumulative voting rights; subject to preferences that may
be applicable to any outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends,
if any, as may be declared from time to time by the Company&#8217;s board of directors out of funds legally available for dividend
payments; holders of common stock have no preferences or rights of conversion, exchange, pre-emption or other subscription rights;
there are no redemption or sinking fund provisions applicable to the common stock; in the event of any liquidation, dissolution
or winding-up of the Company&#8217;s affairs, holders of common stock will be entitled to share ratably in the Company&#8217;s
assets that are remaining after payment or provision for payment of all of the Company&#8217;s debts and obligations and after
liquidation payments to holders of outstanding shares of preferred stock, if any;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>eliminate all references to the previously existing series of preferred stock and authorize 5,000,000 shares of undesignated
preferred stock that may be issued from time to time by the board of directors without further stockholder authorization in one
or more series upon the terms, limitations, voting rights, relative rights and preferences and variations designated by the board
of directors; if issued, preferred stock would have priority over common stock with respect to dividends and other distributions,
including the distribution of assets upon liquidation; although the Company has no present plans to issue any shares of preferred
stock, the issuance of shares of preferred stock, or the issuance of rights to purchase such shares, could decrease the amount
of earnings and assets available for distribution to the holders of common stock, could adversely affect the rights and powers,
including voting rights, of the common stock, and could have the effect of delaying, deterring or preventing a change of control
of the Company or an unsolicited acquisition proposal;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establish a classified board of directors in which directors will be divided into three classes, with the term of office of
the first class to expire at the first annual meeting of stockholders following the initial classification of directors, the term
of office of the second class to expire at the second annual meeting of stockholders following the initial classification of directors,
and the term of office of the third class to expire at the third annual meeting of stockholders following the initial classification
of directors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>permit the board of directors to alter, amend or repeal the bylaws without obtaining stockholder approval;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>require the approval of at least 80% of the shares entitled to vote at an election of directors to adopt, amend or repeal the
bylaws or repeal the provisions of the Restated Certificate regarding the inability of stockholders to call a special meeting of
stockholders, among other provisions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>provide that special meetings of stockholders may be called only by the board of directors acting pursuant to a resolution
adopted by a majority of the total number of authorized directors whether or not there exist any vacancies in previously authorized
directorships;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>prohibit stockholder action by written consent in lieu of a meeting, thereby requiring all stockholder actions to be taken
at a duly called annual or special meeting of stockholders; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>provide for the indemnification of the Company&#8217;s directors and officers to the fullest extent permitted by the Delaware
General Corporation Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The foregoing description is qualified in its
entirety by reference to the Restated Certificate, a copy of which is attached hereto as Exhibit&nbsp;3.1 and is incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 13.5pt 0 0; text-indent: 0.5in"><I>Amendment and Restatement of Bylaws
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0.5in">Effective as of February 14, 2014, the
Company restated its bylaws (the &#8220;Restated Bylaws&#8221;) in connection with the closing of the Company&#8217;s initial
public offering of shares of its common stock. The Company&#8217;s board of directors and stockholders previously approved the
Restated Bylaws to be adopted effective upon the closing of the Company&#8217;s initial public offering. The Restated Bylaws amend
and restate in their entirety the Company&#8217;s bylaws to, among other things:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>permit the board of directors to alter, amend or repeal the bylaws without obtaining stockholder approval; require the approval
of at least 80% of the shares entitled to vote at an election of directors to adopt, amend or repeal the bylaws;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establish a classified board of directors in which directors will be divided into three classes, with the term of office of
the first class to expire at the first annual meeting of stockholders following the initial classification of directors, the term
of office of the second class to expire at the second annual meeting of stockholders following the initial classification of directors,
and the term of office of the third class to expire at the third annual meeting of stockholders following the initial classification
of directors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>prohibit stockholder
action by written consent in lieu of a meeting, thereby requiring all stockholder actions to be taken at a duly called annual
or special meeting of stockholders;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>provide that special meetings of stockholders may be called only by the board of directors acting pursuant to a resolution
adopted by a majority of the total number of authorized directors whether or not there exist any vacancies in previously authorized
directorships;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establish advance notice requirements for nominations for election to the board of directors and for proposals to be acted
upon at stockholder meetings; for example, the Restated Bylaws require that, except in certain cases, to be timely, a stockholder&#8217;s
notice submitting a proposal or director nomination for consideration at the Company&#8217;s annual stockholder meeting must be
delivered to the corporate secretary at the Company&#8217;s principal executive offices not less than 90 or more than 120 days
prior to the first anniversary of the date of the preceding year&#8217;s annual meeting; provided, however, that in the event that
the date of the annual meeting is more than 30 days before or more than 30 days after the anniversary date of the preceding year&#8217;s
annual meeting, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th
day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting
or the close of business on the 10th day following the day on which public announcement of the date of such meeting is first made
by the Company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>set forth the rights, powers and manner of acting of the board of directors and officers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>permit the board of directors to create committees of the board of directors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>provide a forum selection clause stating that, unless the Company consents in writing to the selection of an alternative forum,
a state or federal court located within the State of Delaware the sole and exclusive forum for (a) any derivative action or proceeding
brought on behalf of the Company, (b) any action asserting a claim of breach of a fiduciary duty owed by any director, officer
or other employee to the Company&#8217;s stockholders, (c) any action asserting a claim arising pursuant to any provision of Delaware
law or the Company&#8217;s certificate of incorporation or bylaws, or (d) any action asserting a claim against the Company that
is governed by the internal affairs doctrine; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>provide for the indemnification of the Company&#8217;s directors and officers to the fullest extent permitted by the Delaware
General Corporation Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-indent: 24.5pt">The foregoing description is qualified
in its entirety by reference to the Company&#8217;s Restated Bylaws, a copy of which is attached hereto as Exhibit&nbsp;3.2 and
is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Item 8.01&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Events.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0.5in">On February&nbsp;14, 2014, the Company
closed its initial public offering of 3,100,000 shares of common stock at a price of $12.00 per share for total gross proceeds
of $37,200,000, less underwriting discounts and commissions. In addition, the Company granted the underwriter a 45-day option to
purchase an additional 465,000 shares of common stock to cover over-allotments, if any. Copies of the press releases announcing
the information contained in this Item&nbsp;8.01 is being filed herewith as Exhibits 99.1 and 99.2 and the information contained
therein is incorporated by reference into this Current Report on Form 8-K.</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Item 9.01&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-top: 12pt; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="padding-top: 12pt; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt"><U>Exhibits</U>. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">Restated Certificate of Incorporation of NephroGenex, Inc., effective as of February 14, 2014. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">Restated Bylaws of NephroGenex, Inc., effective as of February 14, 2014. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">Press release dated February 10, 2014. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">Press release dated February 14, 2014.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>SIGNATURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">NEPHROGENEX, INC.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">Date: February 14, 2014</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; font-size: 10pt; text-indent: 0in"><FONT STYLE="font-size: 10pt">/s/ Pierre Legault</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-indent: 0in"></TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Pierre Legault</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt; text-indent: 0in">Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-bottom: 12pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "t1400226_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 40147}]
{"company-data": {"conformed-name": "NephroGenex, Inc.", "cik": "0001338095", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36303", "film-number": "14617335"}, "business-address": {"street1": "79 T.W. ALEXANDER DRIVE", "street2": "4401 RESEARCH COMMONS BLDG., SUITE 290", "city": "RESEARCH TRIANGLE PARK", "state": "NC", "zip": "27709", "phone": "(609) 986-1780"}, "mail-address": {"street1": "79 T.W. ALEXANDER DRIVE", "street2": "4401 RESEARCH COMMONS BLDG., SUITE 290", "city": "RESEARCH TRIANGLE PARK", "state": "NC", "zip": "27709"}, "former-company": {"former-conformed-name": "NephroGenex Inc", "date-changed": "20050907"}}
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of the
Securities Exchange Act
of 1934
Date of Report (Date
of earliest event reported): February 14, 2014
NEPHROGENEX, INC.
(Exact name of registrant
as specified in its charter)
Delaware
001-36303
20-1295171
(state
        or other jurisdiction
of
        incorporation)
(Commission
File
        Number)
(I.R.S.
        Employer
Identification
        No.)
79 T.W. Alexander Drive
4401 Research Common Building
Suite 290
P.O. Box 14188
Research Triangle
        Park, NC
27709
(Address
    of principal executive offices)
(Zip
    Code)
Registrant's
telephone number, including area code: (609) 986-1780
(Former name or
former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02	       Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d)
On
February 14, 2014, James Mitchum became a member of board of directors of NephroGenex, Inc. (the "Company"). As described
in the Registration Statement on Form S-1 (File No. 333-193023) (the "Registration Statement"), the Company's
board of directors previously approved the appointment of Mr. Mitchum to the Company's board of directors, effective upon
the completion of the Company's initial public offering. Mr. Mitchum will be a Class II director with his term expiring
at the annual meeting of stockholders to be held in 2015. Mr. Mitchum has agreed to serve as a member of the audit committee and
the compensation committee of the Company's board of directors. There are no arrangements or understandings between the
Company and any other person pursuant to which Mr. Mitchum was selected as a director, nor are there any transactions between
Mr. Mitchum and the Company in which he has a direct or indirect material interest that the Company is required to report except
as set forth below.
From 2009 to July 2012, Mr. Mitchum served as
President of the Americas for EUSA Pharma (USA), Inc., where he oversaw the streamlining of that business as well as the development,
FDA approval and successful launch of a pediatric oncology drug in 2011. From 2005 to 2008, Mr. Mitchum served as President and
Chief Executive Officer of Enturia, Inc., a privately owned drug-device company, based in Kansas City, Missouri. From 2004 to 2005,
Mr. Mitchum served as the President and Chief Executive Officer of Sanofi-Aventis Group Japan. Mr. Mitchum has also served as a
director on numerous private company and organization boards. Mr. Mitchum earned an MBA in Business from the University of Tennessee
in Knoxville, Tennessee and a Bachelor of Science degree in Business and Math from Milligan College in Johnson City, Tennessee.
On
the date of this Current Report on Form 8-K,
in connection with his appointment as a director,
the
Company's board of directors, subject to an increase in the amount of available options at the next annual meeting, granted
Mr. Mitchum options to purchase 3,076 shares of the Company's common stock, par value $0.001, at fair market value
under the Company's 2005 Stock Option Plan, as amended and restated.
Item 5.03	       Amendments to Articles
of Incorporation or Bylaws; Change in Fiscal Year.
(a)
Amendment and Restatement
of Certificate of Incorporation
On February 14, 2014, the Company
filed a restated certificate of incorporation (the "Restated Certificate") with the Secretary of State of the State
of Delaware in connection with the closing of the Company's initial public offering of shares of its common stock. As described
in the Registration Statement, the Company's board of directors and stockholders previously approved the Restated Certificate
to be effective upon the closing of the initial public offering. The Restated Certificate amends and restates in its entirety the
Company's restated certificate of incorporation, as amended to, among other things:
·
authorize 100,000,000 shares of common stock; holders of common stock are entitled to one vote for each share held of record
on all matters submitted to a vote of the stockholders, and do not have cumulative voting rights; subject to preferences that may
be applicable to any outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends,
if any, as may be declared from time to time by the Company's board of directors out of funds legally available for dividend
payments; holders of common stock have no preferences or rights of conversion, exchange, pre-emption or other subscription rights;
there are no redemption or sinking fund provisions applicable to the common stock; in the event of any liquidation, dissolution
or winding-up of the Company's affairs, holders of common stock will be entitled to share ratably in the Company's
assets that are remaining after payment or provision for payment of all of the Company's debts and obligations and after
liquidation payments to holders of outstanding shares of preferred stock, if any;
·
eliminate all references to the previously existing series of preferred stock and authorize 5,000,000 shares of undesignated
preferred stock that may be issued from time to time by the board of directors without further stockholder authorization in one
or more series upon the terms, limitations, voting rights, relative rights and preferences and variations designated by the board
of directors; if issued, preferred stock would have priority over common stock with respect to dividends and other distributions,
including the distribution of assets upon liquidation; although the Company has no present plans to issue any shares of preferred
stock, the issuance of shares of preferred stock, or the issuance of rights to purchase such shares, could decrease the amount
of earnings and assets available for distribution to the holders of common stock, could adversely affect the rights and powers,
including voting rights, of the common stock, and could have the effect of delaying, deterring or preventing a change of control
of the Company or an unsolicited acquisition proposal;
·
establish a classified board of directors in which directors will be divided into three classes, with the term of office of
the first class to expire at the first annual meeting of stockholders following the initial classification of directors, the term
of office of the second class to expire at the second annual meeting of stockholders following the initial classification of directors,
and the term of office of the third class to expire at the third annual meeting of stockholders following the initial classification
of directors;
·
permit the board of directors to alter, amend or repeal the bylaws without obtaining stockholder approval;
·
require the approval of at least 80% of the shares entitled to vote at an election of directors to adopt, amend or repeal the
bylaws or repeal the provisions of the Restated Certificate regarding the inability of stockholders to call a special meeting of
stockholders, among other provisions;
·
provide that special meetings of stockholders may be called only by the board of directors acting pursuant to a resolution
adopted by a majority of the total number of authorized directors whether or not there exist any vacancies in previously authorized
directorships;
·
prohibit stockholder action by written consent in lieu of a meeting, thereby requiring all stockholder actions to be taken
at a duly called annual or special meeting of stockholders; and
·
provide for the indemnification of the Company's directors and officers to the fullest extent permitted by the Delaware
General Corporation Law.
The foregoing description is qualified in its
entirety by reference to the Restated Certificate, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein
by reference.
Amendment and Restatement of Bylaws
Effective as of February 14, 2014, the
Company restated its bylaws (the "Restated Bylaws") in connection with the closing of the Company's initial
public offering of shares of its common stock. The Company's board of directors and stockholders previously approved the
Restated Bylaws to be adopted effective upon the closing of the Company's initial public offering. The Restated Bylaws amend
and restate in their entirety the Company's bylaws to, among other things:
·
permit the board of directors to alter, amend or repeal the bylaws without obtaining stockholder approval; require the approval
of at least 80% of the shares entitled to vote at an election of directors to adopt, amend or repeal the bylaws;
·
establish a classified board of directors in which directors will be divided into three classes, with the term of office of
the first class to expire at the first annual meeting of stockholders following the initial classification of directors, the term
of office of the second class to expire at the second annual meeting of stockholders following the initial classification of directors,
and the term of office of the third class to expire at the third annual meeting of stockholders following the initial classification
of directors;
·
prohibit stockholder
action by written consent in lieu of a meeting, thereby requiring all stockholder actions to be taken at a duly called annual
or special meeting of stockholders;
·
provide that special meetings of stockholders may be called only by the board of directors acting pursuant to a resolution
adopted by a majority of the total number of authorized directors whether or not there exist any vacancies in previously authorized
directorships;
·
establish advance notice requirements for nominations for election to the board of directors and for proposals to be acted
upon at stockholder meetings; for example, the Restated Bylaws require that, except in certain cases, to be timely, a stockholder's
notice submitting a proposal or director nomination for consideration at the Company's annual stockholder meeting must be
delivered to the corporate secretary at the Company's principal executive offices not less than 90 or more than 120 days
prior to the first anniversary of the date of the preceding year's annual meeting; provided, however, that in the event that
the date of the annual meeting is more than 30 days before or more than 30 days after the anniversary date of the preceding year's
annual meeting, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th
day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting
or the close of business on the 10th day following the day on which public announcement of the date of such meeting is first made
by the Company;
·
set forth the rights, powers and manner of acting of the board of directors and officers;
·
permit the board of directors to create committees of the board of directors;
·
provide a forum selection clause stating that, unless the Company consents in writing to the selection of an alternative forum,
a state or federal court located within the State of Delaware the sole and exclusive forum for (a) any derivative action or proceeding
brought on behalf of the Company, (b) any action asserting a claim of breach of a fiduciary duty owed by any director, officer
or other employee to the Company's stockholders, (c) any action asserting a claim arising pursuant to any provision of Delaware
law or the Company's certificate of incorporation or bylaws, or (d) any action asserting a claim against the Company that
is governed by the internal affairs doctrine; and
·
provide for the indemnification of the Company's directors and officers to the fullest extent permitted by the Delaware
General Corporation Law.
The foregoing description is qualified
in its entirety by reference to the Company's Restated Bylaws, a copy of which is attached hereto as Exhibit 3.2 and
is incorporated herein by reference.
Item 8.01	       Other Events.
On February 14, 2014, the Company
closed its initial public offering of 3,100,000 shares of common stock at a price of $12.00 per share for total gross proceeds
of $37,200,000, less underwriting discounts and commissions. In addition, the Company granted the underwriter a 45-day option to
purchase an additional 465,000 shares of common stock to cover over-allotments, if any. Copies of the press releases announcing
the information contained in this Item 8.01 is being filed herewith as Exhibits 99.1 and 99.2 and the information contained
therein is incorporated by reference into this Current Report on Form 8-K.
Item 9.01	       Financial Statements and Exhibits
(d)
Exhibits
.
3.1
Restated Certificate of Incorporation of NephroGenex, Inc., effective as of February 14, 2014.
3.2
Restated Bylaws of NephroGenex, Inc., effective as of February 14, 2014.
99.1
Press release dated February 10, 2014.
99.2
Press release dated February 14, 2014.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEPHROGENEX, INC.
Date: February 14, 2014
/s/ Pierre Legault
Pierre Legault
Chief Executive Officer